Heart rate-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease: A randomized, double-blind, placebo-controlled, crossover study

American Journal of Cardiovascular Drugs

Volumn 12, Issue 3, 2012, Pages 179-188

  Majewski, Sebastian ^a   Slomka, Sebastian ^a   Zielinska Wyderkiewicz, Ewa ^a   Ciebiada, MacIej ^a   Gorski, Pawel ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Heart rate; Ivabradine; Obstructive airway disorders.

Indexed keywords

IVABRADINE; PLACEBO;

ADULT; AGED; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; FATIGUE; FEMALE; FORCED VITAL CAPACITY; HEADACHE; HEART RATE; HUMAN; LUNG FUNCTION; MALE; NAUSEA; OUTCOME ASSESSMENT; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN; TREATMENT DURATION; VISUAL DISORDER;

ADULT; AGED; ASTHMA; BENZAZEPINES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 84861325669     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11597400-000000000-00000     Document Type: Article

References (57)

1. Kannel WB, Kannel C, Paffenbarger RS, et al. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart 1987; 113: 1489-94 (Pubitemid 17092823)
2. Palatini P, Casiglia E, Pauletto P, et al. Relationship of tachycardia with high blood pressure and metabolic abnormalities: a study with a mixture analysis in three populations. Hypertens 1997; 30: 1267-73 (Pubitemid 27476189)
3. Hjalmarson A, Gilpin EA, Kjekshus G, et al. Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol 1990; 1: 547-53 (Pubitemid 20091878)
4. Kjekshus J, Gullestad L. Heart rate as a therapeutic target in heart failure. Eur Heart J Supplements 1999; 1 (Suppl. H): H64-9 (Pubitemid 29304286)
5. Gillum RF, Makuc DM, Feldman JJ. Pulse rate, coronary heart disease, and death: theNHANESI Epidemiologic Follow-up Study.AmHeart J 1991; 121no. 1: 172-7
6. Fox K, Borer JS, Camm AJ, et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007 Aug 28; 50 (9): 823-30 (Pubitemid 47277500)
7. Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318: 1730-7 (Pubitemid 29290470)
8. Frishman WH, Furberg CD, Friedewald WT. The use of beta-adrenergic blocking drugs in patients with myocardial infarction. Curr Probl Cardiol 1984; 9: 1-50
9. Gheorghiade M, Goldstein S. Beta-blockers in the post-myocardial infarction patient. Circulation 2002; 4: 394-8
10. Farrell MH, Foody JM, Krumholz HM. Beta-blockers in heart failure: clinical applications. JAMA 2002; 7: 890-7 (Pubitemid 34252038)
11. Fihn SD, Williams SV, Daley J, et al. Guidelines for the management of patients with chronic stable angina: treatment. Ann Intern Med 2001; 135 (8 Pt 1): 616-32 (Pubitemid 33010199)
12. Benson MK, Berrill WT, Cruickshank JM, et al. A comparison of four etaadrenoceptor antagonists in patients with asthma. Br J Clin Pharmacol 1978; 5: 415-9 (Pubitemid 8325684)
13. Schwartz S, Davies S, Juers JA. Life-threatening cold and exercise induced asthma potentiated by administration of propranolol. Chest 1980; 78: 100-1 (Pubitemid 10090332)
14. Wiliams IP, Millard FJC. Severe asthma after inadvertent ingestion of oxprenolol. Thorax 1980; 35: 160
15. Chang CL, Mills GD, McLachlan JD, et al. Cardio-selective and non-selective beta-blockers in chronic obstructive pulmonary disease: effects on bronchodilator response and exercise. Intern Med J. 2010 Mar; 40 (3): 193-200
16. DiFrancesco D, Camm JA. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs 2004; 64: 1757-65 (Pubitemid 39215187)
17. Tendera M. If inhibition: from pure heart rate reduction to treatment of stable angina. Eur Heart J Suppl. 2005; 7 Suppl. H: H3-6 (Pubitemid 41298037)
18. Babu KS, Gadzik F, Holgate ST. Absence of respiratory effects with ivabradine in patients with asthma. Br J Clin Pharmacol 2008 Jul; 66 (1): 96-101 (Pubitemid 351822157)
19. Ageev FT, Makarova GV, Patrusheva IF, et al. The efficacy and safety of the combination of b-blocker bisoprolol and I(f) inhibitor ivabradine in patients ith stable angina and chronic obstructive pulmonary disease. Kardiologiia 2010; 50 (10): 22-6
20. Beasley R. The global burden of asthma report, Global Initiative for Asthma (GINA) 2004 [online]. Available from URL: http://www.ginasthma.org [Accessed 2011 Sep 7]
21. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010 [online]. Available from URL: http://www.goldcopd.org [Accessed 2011 Sep 7]
22. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term myocardial infarction intervention trials. Am J Cardiol 1986; 57: 43F-9F (Pubitemid 16054097)
23. Lechat P. Beta-blocker treatment in heart failure: role of heart rate reduction. Basic Res Cardiol 1998; 93 Suppl. 1: 148-55 (Pubitemid 28499482)
24. Fox K, Garcia MA, ArdissinoD, et al. Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J2006; 27: 1341-81 (Pubitemid 43998110)
25. Ford ES, Giles WH, Croft JB. Prevalence of nonfatal coronary heart disease among American adults. Am Heart J 2000; 139: 371-7 (Pubitemid 30149182)
26. Lipworth BJ, Irvine NA, McDevitt DG. The effects of chronic dosing on the beta 1 and beta 2-adrenoceptor antagonism of betaxolol and atenolol. Eur JClin Pharmacol. 1991; 40 (5): 467-71
27. Lammers JW, Folgering HT, van Herwaarden CL. Respiratory tolerance of bisoprolol and metoprolol in asthmatic patients. J Cardiovasc Pharmacol 1986; 8 Suppl. 11: S69-73 (Pubitemid 17086488)
28. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388-442
29. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: areport of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112: e154-235
30. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for reversible airway disease. Cochrane Database Syst Rev 2002; (4): CD002992
31. Salpeter SR, Ormiston TM, Salpeter EE, et al. Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. Respir Med 2003 Oct; 97 (10): 1094-101 (Pubitemid 37185112)
32. Dransfield MT, Rowe SM, Johnson JE, et al. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax 2008 Apr; 63 (4): 301-5 (Pubitemid 351497940)
33. van Gestel YR, Hoeks SE, Sin DD, et al. Impact of cardioselective betablockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med 2008 Oct 1; 178 (7): 695-700
34. Short PM, Lipworth SI, Elder DH, et al. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ 2011 May 10; 342: d2549.doi: 10.1136/bmj.d2549
35. Baker JG. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol 2005 Feb; 144 (3): 317-22 (Pubitemid 40313677)
36. van der Woude HJ, Zaagsma J, Postma DS, et al. Detrimental effects of betablockers in COPD: a concern for nonselective b-blockers. Chest 2005; 127: 818-24 (Pubitemid 40775510)
37. Lee DK, Borade PS, Currie GP. Safety of beta-blockers in COPD: the jury must still be out. QJM 2005 Sep; 98 (9): 706-7 (Pubitemid 41236101)
38. Albouaini K, Andron M, Alahmar A, et al. Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. Int J Chron Obstruct Pulmon Dis 2007; 2: 535-40
39. Egred M, Shaw S, Mohammad B, et al. Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. Q J Med 2005; 98: 493-7 (Pubitemid 41418672)
40. Brooks TW, Creekmore FM, Young DC, et al. Rates of hospitalizations and emergency department visits in patients with asthma and chronic obstructive pulmonary disease taking beta-blockers. Pharmacotherapy 2007 May; 27 (5): 684-90 (Pubitemid 46700960)
41. Masoli M, Fabian D, Holt S, et al. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59 (5): 469-78 (Pubitemid 38580764)
42. Roche N, Huchon G. Epidemiology of chronic obstructive pulmonary disease. Rev Prat 2004 Sep 15; 54 (13): 1408-13 (Pubitemid 39256298)
43. Antonelli Inclazi R, Fuso L, De Rosa M, et al. Co-morbidity contributes to predict mortality of patients with obstructive pulmonary disease. Eur Respir J1997; 10: 2794-800 (Pubitemid 28052790)
44. Cazzola M, Calzetta L, Bettoncelli G, et al. Asthma and comorbid medical illness. Eur Respir J 2011 Jul; 38 (1): 42-9
45. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of betaagonists in patients with asthma and COPD: a meta-analysis. Chest 2004 Jun; 125 (6): 2309-21 (Pubitemid 38796452)
46. Sears MR. Adverse effects of beta-agonists. J Allergy Clin Immunol 2002; 110: S322-8
47. Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left ventricular systolic dysfunction (BEAUTIFUL): arandomised, double-blind, placebo-controlled trial. Lancet 2008 Sep 6; 372 (9641): 807-16
48. Borer JS, Fox K, Jaillon P, et al. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 2003; 107: 817-23 (Pubitemid 36241038)
49. Tardif JC, Ford I, Tendera M, et al. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26: 2529-36 (Pubitemid 41677303)
50. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010 Sep 1; 376 (9744): 875-85
51. Murata GH, Lium DJ, Busby HK, et al. Precision and accuracy of selfmeasured peak expiratory flow rates in chronic obstructive pulmonary disease. South Med J 1998 Oct; 91 (10): 919-24 (Pubitemid 28476290)
52. Murata GH, Kapsner CO, Lium DJ, et al. Patient compliance with peak flow monitoring in chronic obstructive pulmonary disease. Am J Med Sci 1998 May; 315 (5): 296-301 (Pubitemid 28196941)
53. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/ formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003 Jan; 21 (1): 74-81 (Pubitemid 36150304)
54. Llewellin P, Sawyer G, Lewis S, et al. The relationship between FEV1 and PEF in the assessment of the severity of airways obstruction. Respirology 2002 Dec; 7 (4): 333-7
55. Kaneko A, Tachibana M. A voltage-clamp analysis of membrane currents in solitary bipolar cells dissociated from Carassius aureus. J Physiol 1985; 358: 131-52 (Pubitemid 15150538)
56. Demontis GC, Longoni B, Barcaro U, et al. Properties and functional roles of hyperpolarization-gated currents in guinea-pig retinal rods. J Physiol 1999; 515: 813-28 (Pubitemid 29140115)
57. Satoh TO, Yamada M. A bradycardiac agent ZD7288 blocks the hyperpolarization- activated current (I(h)) in retinal rod photoreceptors. Neuropharmacology 2000; 39: 1284-91 (Pubitemid 30173192)